Imaging Follow-up After Stone Treatment

November 12, 2026 updated by: Panagiotis Neofytou, National and Kapodistrian University of Athens

Imaging Follow-up of Patients With Urinary Stones: Ultrasound-Based Randomized Controlled Trial

Kidney stones are a common condition that can recur even after successful treatment. Regular imaging tests can help detect new stones, but frequent use of X-rays and CT scans can expose patients to unnecessary radiation. It is not yet clear how often patients should have imaging tests after treatment.

This study compares two schedules for monitoring patients who have undergone treatment for kidney stones and have no significant remaining stones. Participants are randomly assigned to one of two groups. One group has an ultrasound examination of the kidneys and urinary tract every 6 months, while the other group has the same examination every 12 months.

The study aims to determine whether more frequent ultrasound examinations can reduce unexpected episodes related to kidney stones, such as pain, bleeding in the urine, or urinary infections caused by blocked urine flow.

The researchers will also assess changes in kidney function, visits to the emergency department, the number of imaging tests performed, the development or growth of stones without symptoms, and the overall cost of imaging.

The study includes adults with a low or high risk of kidney stones recurrence and is conducted at Sismanoglio General Hospital in Athens, Greece.

The findings may help determine an appropriate schedule for monitoring patients after kidney stone treatment while reducing unnecessary tests, radiation exposure, and healthcare costs.

Study Overview

Study Type

Interventional

Enrollment (Estimated)

160

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

    • Attica
      • Athens, Attica, Greece, 15126
        • 2nd Department of Urology, Sismanoglio General Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Adults aged 18 years or older, including both males and females.
  • Patients with urolithiasis of any stone composition.
  • Patients with stones at any anatomical location.
  • Patients undergoing any definitive stone treatment procedure, including extracorporeal shock wave lithotripsy (SWL), ureteroscopy (URS), retrograde intrarenal surgery (RIRS), or percutaneous nephrolithotomy (PCNL).
  • Patients classified as either low-risk or high-risk for stone recurrence according to European Association of Urology (EAU) criteria.
  • Patients with no significant residual stone fragments following treatment, defined as the absence of residual fragments larger than 2 mm at 4-6 weeks after the procedure, assessed by radiography and ultrasound or low-dose computed tomography.

Exclusion Criteria:

  • Refusal to participate in the study.
  • Patients with anatomical abnormalities or a history of previous open surgery for stone disease.
  • Patients with a solitary kidney or chronic kidney disease.
  • Patients with occupations considered to be associated with a high risk of stone disease, such as pilots.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: 6-monthly ultrasound follow-up

kidney, ureter, bladder ultrasound every 6 months

kidney, ureter, bladder ultrasound every 12 months

Active Comparator: 12-monthly ultrasound follow-up

kidney, ureter, bladder ultrasound every 6 months

kidney, ureter, bladder ultrasound every 12 months

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Incidence of Symptomatic Stone Episodes
Time Frame: from randomization until the end of follow-up period, 1 year after intervention

Occurrence of symptomatic stone episodes during a one-year follow-up period, defined as any of the following: a new episode of renal colic or pain, hematuria not attributable to another cause, or urinary tract infection associated with obstruction caused by a newly formed stone.

In patients with no visible residual stone fragments after treatment, the detection of any stone during follow-up will be considered recurrence. In patients with residual fragments smaller than 2 mm, detection of any fragment measuring 3 mm or larger will be considered recurrence.

from randomization until the end of follow-up period, 1 year after intervention

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Estimated Glomerular Filtration Rate (eGFR)
Time Frame: from randomization until the end of follow-up period, 1 year after intervention

Change in estimated glomerular filtration rate (eGFR) during the follow-up period, as an indicator of changes in kidney function.

from randomization until the end of follow-up period, 1 year after intervention
Number of Emergency Department Visits
Time Frame: from randomization until the end of follow-up period, 1 year after intervention

Number of visits to the emergency department during the follow-up period.

from randomization until the end of follow-up period, 1 year after intervention
Number of Imaging Examinations Performed
Time Frame: from randomization until the end of follow-up period, 1 year after intervention

Total number of imaging examinations performed during the follow-up period for the evaluation of urolithiasis, including plain radiographs, computed tomography scans, and ultrasound examinations.

from randomization until the end of follow-up period, 1 year after intervention
Incidence of Asymptomatic Stone Growth
Time Frame: from randomization until the end of follow-up period, 1 year after intervention

Number of patients who develop asymptomatic stone growth during the follow-up period, as detected by imaging examinations.

from randomization until the end of follow-up period, 1 year after intervention
Total Cost of Imaging Examinations
Time Frame: from randomization until the end of follow-up period, 1 year after intervention

Total cost of imaging examinations performed during the follow-up period for the evaluation and monitoring of urolithiasis.

from randomization until the end of follow-up period, 1 year after intervention

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

November 1, 2026

Primary Completion (Estimated)

November 1, 2027

Study Completion (Estimated)

January 1, 2028

Study Registration Dates

First Submitted

November 4, 2026

First Submitted That Met QC Criteria

November 12, 2026

First Posted (Actual)

November 18, 2026

Study Record Updates

Last Update Posted (Actual)

November 18, 2026

Last Update Submitted That Met QC Criteria

November 12, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe